Viatris Inc. agreed to settle litigation over allegations it colluded with Pfizer Inc. over the pricing of EpiPen. A certified class of consumers and third-party payers brought the suit claiming that, as a result of a conspiracy between Mylan (now Viatris) and Pfizer to inhibit the availability of cheaper products, consumers overpaid for the potentially life-saving drug. The judge presiding over the case in the U.S. District Court for the District of Kansas ordered a fairness hearing for July, and, as a result, final approval is pending.